Skip to Content
Search Menu

EHA l European Hematology Association’s Annual Congress

EHA 2025

EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy 

  • / Jan Andreasen

Fredrik Hellem Schjesvold

Real-World Insights on Belantamab Mafodotin in RRMM

/ Fredrik Schjesvold
EHA25Myeloma Play the Video

EHA 2024

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

  • / BestPractice Nordic
Malin Rasmussen

EHA 2025: Radiotherapy in FL Linked to Low Relapse Rates

/ Malin Rasmussen
EHA25Lymphoma Play the Video

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymphoma

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Maria Eugenia Chollet

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

/ Maria Eugenia Chollet
EHA24 Play the Video
Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myeloma Play the Video
Sergio Martinez Høyer

An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies

/ Sergio Martinez Høyer
EHA24 Play the Video
Frida Bugge Askeland

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Frida Bugge Askeland
EHA24Myelooma Play the Video
Sigrid S. Skånland

From Genomic Precision Medicine to Functional Precision Medicine in Hematology

/ Sigrid S. Skånland
EHA24 Play the Video
Henrik Hjorth-Hansen

Management of CML in Adults: 2024 ELN Recommendations

/ Henrik Hjorth-Hansen
EHA24 Play the Video
Rasmus Rask Kragh Jørgensen

Development of Prediction Models for Survival among Hodgkin Lymphoma Patients

/ Rasmus Rask Kragh Jørgensen
EHA24Hodgkin’s lymphoma Play the Video
Ângela Mesquita

Better Predictor of Treatment Efficacy of Myelodysplastic Syndromes

/ Ângela Sofia Gerós Mesquita
EHA24 Play the Video
Load more

EHA 2023

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

/ Hematology / Anna Sureda Balari

Gilteritinib for Patients with Newly Diagnosed AML

/ Hematology / Mark Levis

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Hematology / Arnon Kater

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Hematology / Evangelos Terpos

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

/ Hematology / Ryan Jacobs
Se oversigt

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Hematology / Barbara Eichhorst

Risk of Dementia in Older Patients Treated with Chemotherapy for Lymphoma

/ Hematology / Eva Futtrup Maksten

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Hematology / Evangelos Terpos / Jan Andreasen

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

/ Hematology / Alan Z. Skarbnik

UK Trial Gives Voice to CLL Patients’ Experiences with Targeted Therapies

/ Hematology / Dima El-Sharkawi
Se oversigt

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

/ Hematology / Carl Sandén

EHA 2025: Tripled Cardiac Morbidity Risk After Hodgkin Lymphoma Therapy

/ Hematology / Sara Rossetti

EHA 2025: Overcoming Venetoclax Resistance

/ Hematology / Justinas Daraskevicius

EHA 2025: First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL

/ Hematology / Lydia Scarfò

EHA 2025: ADHD Treatment medication alleviate Fatigue in Patients with Malignant Diseases show Danish Study

/ Hematology / Henrik Frederiksen
Se oversigt

ASH | Congress

We cover the most interesting news from the ASH Congress through abstracts, online articles and MEDtalk videos from experts and specialists worldwide.

Go to page

More from EHA

Mats Jerkeman

Several Options for Frontline Treatment of MCL

/ Mats Jerkeman
EHA25Lymphoma Play the Video
Paolo Ghia

EHA 2025: Durable Undetectable MRD Responses with Acalabrutinib in CLL

/ Paolo Ghia
CLLEHA25 Play the Video
Mats Jerkeman

EHA 2025: Signs of Functional Cure for MCL in 25 Years Nordic Follow-Up Study

/ Mats Jerkeman
EHA25Lymphoma Play the Video
Chan Cheah

EHA 2025: Sonrotoclax + Zanubrutinib Show Durable Responses in R/R CLL/SLL

/ Chan Cheah
CLLEHA25 Play the Video
Paolo Ghia

EHA 2025: Zanubrutinib Effective as First-Line CLL/SLL Therapy Regardless of del(17p)

/ Paolo Ghia
CLLEHA25 Play the Video
Hanne Norseth

EHA 2025: TG01 Shows Promise in KRAS-Mutated Myeloma

/ Hanne Norseth
EHA25Myeloma Play the Video

The 2025 EHA Award Recipients

/ Amanda Feldballe Bernholm
EHA25
Anne Louise Tølbøll Sørensen

EHA 2025: Nordic AML Group Explores Optimized Regimen for AML Patients

/ Anne Louise Tølbøll Sørensen
AMLEHA25 Play the Video
Frida Bugge Askeland

EHA 2025: Impact of Treating MRD Relapse Post 1L in Multiple Myeloma

/ Frida Bugge Askeland
EHA25Myelooma Play the Video
Load more

Back to top